558 related articles for article (PubMed ID: 32987705)
1. IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis.
Marchant V; Tejera-Muñoz A; Marquez-Expósito L; Rayego-Mateos S; Rodrigues-Diez RR; Tejedor L; Santos-Sanchez L; Egido J; Ortiz A; Valdivielso JM; Fraser DJ; López-Cabrera M; Selgas R; Ruiz-Ortega M
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32987705
[TBL] [Abstract][Full Text] [Related]
2. IL-17A is a novel player in dialysis-induced peritoneal damage.
Rodrigues-Díez R; Aroeira LS; Orejudo M; Bajo MA; Heffernan JJ; Rodrigues-Díez RR; Rayego-Mateos S; Ortiz A; Gonzalez-Mateo G; López-Cabrera M; Selgas R; Egido J; Ruiz-Ortega M
Kidney Int; 2014 Aug; 86(2):303-15. PubMed ID: 24552849
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure.
López-Cabrera M; Aguilera A; Aroeira LS; Ramírez-Huesca M; Pérez-Lozano ML; Jiménez-Heffernan JA; Bajo MA; del Peso G; Sánchez-Tomero JA; Selgas R
Perit Dial Int; 2006; 26(1):26-34. PubMed ID: 16538870
[TBL] [Abstract][Full Text] [Related]
4. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
Sandoval P; Loureiro J; González-Mateo G; Pérez-Lozano ML; Maldonado-Rodríguez A; Sánchez-Tomero JA; Mendoza L; Santamaría B; Ortiz A; Ruíz-Ortega M; Selgas R; Martín P; Sánchez-Madrid F; Aguilera A; López-Cabrera M
Lab Invest; 2010 Oct; 90(10):1517-32. PubMed ID: 20531289
[TBL] [Abstract][Full Text] [Related]
5. The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis.
Ferrantelli E; Liappas G; Vila Cuenca M; Keuning ED; Foster TL; Vervloet MG; Lopéz-Cabrera M; Beelen RH
Kidney Int; 2016 Mar; 89(3):625-35. PubMed ID: 26880457
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.
Fan YP; Hsia CC; Tseng KW; Liao CK; Fu TW; Ko TL; Chiu MM; Shih YH; Huang PY; Chiang YC; Yang CC; Fu YS
Stem Cells Transl Med; 2016 Feb; 5(2):235-47. PubMed ID: 26718649
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 During Unfavorable Peritoneal Tissue Remodeling in Patients Receiving Peritoneal Dialysis as Renal Replacement Therapy.
Catar RA; Bartosova M; Kawka E; Chen L; Marinovic I; Zhang C; Zhao H; Wu D; Zickler D; Stadnik H; Karczewski M; Kamhieh-Milz J; Jörres A; Moll G; Schmitt CP; Witowski J
Front Immunol; 2022; 13():821681. PubMed ID: 35185912
[TBL] [Abstract][Full Text] [Related]
8. Update on mechanisms of ultrafiltration failure.
Kim YL
Perit Dial Int; 2009 Feb; 29 Suppl 2():S123-7. PubMed ID: 19270200
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal dialysate-range hypertonic glucose promotes T-cell IL-17 production that induces mesothelial inflammation.
Helmke A; Hüsing AM; Gaedcke S; Brauns N; Balzer MS; Reinhardt M; Hiss M; Shushakova N; de Luca D; Prinz I; Haller H; von Vietinghoff S
Eur J Immunol; 2021 Feb; 51(2):354-367. PubMed ID: 32926407
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal transformation shortly after kidney transplantation in pediatric patients with preceding chronic peritoneal dialysis.
Zhang C; Bartosova M; Marinovic I; Schwab C; Schaefer B; Vondrak K; Ariceta G; Zaloszyc A; Ranchin B; Taylan C; Büscher R; Oh J; Mehrabi A; Schmitt CP
Nephrol Dial Transplant; 2023 Sep; 38(10):2170-2181. PubMed ID: 36754369
[TBL] [Abstract][Full Text] [Related]
11. Long-term intervention with heparins in a rat model of peritoneal dialysis.
Schilte MN; Loureiro J; Keuning ED; ter Wee PM; Celie JW; Beelen RH; van den Born J
Perit Dial Int; 2009; 29(1):26-35. PubMed ID: 19164250
[TBL] [Abstract][Full Text] [Related]
12. Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model.
Vila Cuenca M; Keuning ED; Talhout W; Paauw NJ; van Ittersum FJ; Ter Wee PM; Beelen RHJ; Vervloet MG; Ferrantelli E
Int Urol Nephrol; 2018 Jun; 50(6):1151-1161. PubMed ID: 29728994
[TBL] [Abstract][Full Text] [Related]
13. Factors increasing severity of peritonitis in long-term peritoneal dialysis patients.
Park MS
Adv Ren Replace Ther; 1998 Jul; 5(3):185-93. PubMed ID: 9686629
[TBL] [Abstract][Full Text] [Related]
14. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions.
Aroeira LS; Aguilera A; Sánchez-Tomero JA; Bajo MA; del Peso G; Jiménez-Heffernan JA; Selgas R; López-Cabrera M
J Am Soc Nephrol; 2007 Jul; 18(7):2004-13. PubMed ID: 17568021
[TBL] [Abstract][Full Text] [Related]
15. Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis.
Trionfetti F; Marchant V; González-Mateo GT; Kawka E; Márquez-Expósito L; Ortiz A; López-Cabrera M; Ruiz-Ortega M; Strippoli R
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982834
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Shi Y; Ni J; Tao M; Ma X; Wang Y; Zang X; Hu Y; Qiu A; Zhuang S; Liu N
Ren Fail; 2020 Nov; 42(1):890-901. PubMed ID: 32862739
[TBL] [Abstract][Full Text] [Related]
18. Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis.
de Lima SM; Otoni A; Sabino Ade P; Dusse LM; Gomes KB; Pinto SW; Marinho MA; Rios DR
Clin Chim Acta; 2013 Jun; 421():46-50. PubMed ID: 23466603
[TBL] [Abstract][Full Text] [Related]
19. Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis.
Liappas G; González-Mateo G; Aguirre AR; Abensur H; Albar-Vizcaino P; Parra EG; Sandoval P; Ramírez LG; Del Peso G; Acedo JM; Bajo MA; Selgas R; Sánchez Tomero JA; López-Cabrera M; Aguilera A
Oncotarget; 2016 May; 7(21):30133-46. PubMed ID: 27102153
[TBL] [Abstract][Full Text] [Related]
20. [Selected indices of peritoneal fibrosis in patients undergoing peritoneal dialysis].
Penar J; Weyde W; Krajewska M; Madziarska K; Gołebiowski T; Szymczak M; Kłak R; Klinger M
Postepy Hig Med Dosw (Online); 2009 Apr; 63():200-4. PubMed ID: 19502680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
